Meet the 2026 Lymphoma Research Mentoring Program Grantees The Lymphoma Research Foundation’s Lymphoma Scientific Research Mentoring Program (LSRMP) is a first-of-its-kind education and mentoring program for junior scientists who wish to focus on lymphoma and CLL research, whether in the…
Lymphoma Research Foundation Announces International T-Cell Lymphomas Consortium New initiative will unite researchers worldwide to accelerate progress in rare and aggressive T-cell lymphomas. NEW YORK, Sept. 1 – The Lymphoma Research Foundation today announced the launch of the International T-cell…
The 13 Career Development Award and Postdoctoral Fellowship research grants include projects exploring numerous disease subtypes treatments, including rare disease states like T-cell lymphomas, as well as novel therapeutics.
Lymphoma Research Foundation Awards 24 New Scientific Research Grants Nearly $4 Million Awarded to Advance Critical Cancer Research The Lymphoma Research Foundation — the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and serving the lymphoma community…
Updates from the 2025 American Society of Hematology Annual Meeting The Lymphoma Research Foundation returned to the American Society of Hematology (ASH) Annual Meeting and Exposition, with 276 Foundation-affiliated scientists, including past and present members of the Foundation’s world-leading Scientific…
Patient Perspectives: Access to CAR T-Cell Therapy One of the most revolutionary breakthroughs in cancer care comes from within a patient’s own cells: chimeric antigen receptor (CAR) T-cell therapy, which harnesses the powers of the body’s immune system to hone…
ASH 2025: Association Between Adolescent and Young Adult (AYA) Age, Acuity of Illness at Diagnosis, and Clinical Trial Enrollment Among Patients with Hematologic Malignancies at a Pediatric Center Clinical trials represent an important opportunity to access cutting edge therapies in…
ASH 2025: Real-World Treatment Patterns, Patient Characteristics, and Outcomes of CBTKI-Based Therapies Amongst a Contemporary Cohort of Patients with R/R MCL in the United States Covalent Bruton tyrosine kinase inhibitors (cBTKis) have been a cornerstone of treatment for relapsed/refractory mantle…
ASH 2025: A Newly Identified Role for IL-5 in Regulating CAR T-associated Toxicity and Efficacy Chimeric antigen receptor (CAR) T-cell therapies have emerged as an important component of the treatment arsenal for B-cell malignancies. Their use, however, has been complicated…
ASH 2025: Sasp-Driven Immune Evasion Defines a Novel African Ancestry-Associated DLBCL Subtype with Distinctive Molecular and Immune Vulnerabilities African Americans with diffuse large B-cell lymphoma (DLBCL) are susceptible to cancer development at an earlier age and worse survival outcomes. Genetics…
